Navigation Links
NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
Date:7/27/2009

EMERYVILLE, Calif., July 27 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will present at the Jesup & Lamont 2009 Growth Stock Conference organized by the LifeTech Capital Group on Thursday, July 30, 2009 at 9:30 am EDT. The presentation will be held at The Boca Raton Resort & Club in Boca Raton, Florida.

Dr. Najafi will provide a corporate overview and highlight NovaBay's clinical progress, business development strategy and product development candidates. His presentation will:

  • update investors on NovaBay's internal clinical programs in hospital-associated infections and respiratory infections.
  • provide information on NovaBay's recent announcements regarding the initiation of a Phase II clinical trial for the use of NovaBay's lead Aganocide(R) compound, NVC-422, for viral conjunctivitis, which is being conducted by its partner Alcon (NYSE: ACL).
  • review the recently announced partnership with Galderma, the world's leading dermatology company, for development of acne and impetigo products
  • discuss the important collaborative agreement with professors Markus Nagl, M.D. and Waldemar Gottardi, Ph.D. of the Medical University of Innsbruck, Austria, which broadens NovaBay's intellectual property estate, expands its pre-clinical pipeline and advances the development of NovaBay's Aganocide compounds by integrating on-going clinical work at the Medical University with NovaBay's development programs.

In addition, Dr. Najafi will serve on a key conference panel that will include industry leaders and a former FDA Commissioner to discuss trends in the biotech industry and biotech investing. The panel session will take place at 4:45 pm EDT on Wednesday, July 29, 2009.

About Aganocide Compounds

The Aganocide compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically developed by NovaBay to mimic the body's natural defense against infection. The Aganocide compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated, first-in-class, small molecule, patented new chemical entities may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of antibiotic-resistant bacterial strains. In preclinical testing, the Aganocide compounds have been shown to be highly effective against bacteria, including its multi-drug resistant strains, viruses and fungi. They also have been demonstrated to be effective against bacteria in biofilms, which render most antibiotics ineffective. Aganocides have a broad therapeutic index while providing a high degree of potency and tolerability as well as dosing versatility and flexibility.

About NovaBay

NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic, anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing dermatological, hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as in contact lens care solutions. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. For more information on NovaBay, visit: www.novabaypharma.com.


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board
2. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
3. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
4. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
5. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
6. NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region
7. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
8. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
9. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
10. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
11. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... 1, 2016 asking the Federal Drug Administration (FDA) to consider OA as a ... OARSI is concerned about the growing population of OA patients, many of whom ...
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical ... it has acquired the assets of Theorem Clinical Research - Clinical Supplies ... clinical trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials ...
(Date:12/6/2016)... 6, 2016  SRI International has been awarded ... the National Institutes of Health,s National Institute of ... AIDS (NIAID-DAIDS) to support the manufacturing and characterization ... agents. Under the seven-year contract, SRI will provide ... for candidate HIV-prevention products that emerge from investigator-initiated ...
(Date:12/5/2016)... Axovant Sciences Ltd. (NYSE: AXON ... treatment of dementia, today announced that data on the ... disease will be presented at the 2016 Clinical Trials ... 2016 in San Diego . Intepirdine ... and complex measures of activities of daily living (ADLs) ...
Breaking Biology Technology:
(Date:11/22/2016)... 22, 2016 According to the new market research ... Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and ... the market is expected to grow from USD 10.74 Billion in 2015 ... between 2016 and 2022. Continue Reading ... ...
(Date:11/21/2016)... 2016   Neurotechnology , a provider of ... announced that the MegaMatcher On Card fingerprint matching ... the NIST Minutiae Interoperability Exchange (MINEX) III ... steps of the evaluation protocol. ... of fingerprint templates used to establish compliance of ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):